Ependymoblastoma associated with prenatal exposure to diphenylhydantoin and methylphenobarbitone
- 1 May 1985
- Vol. 55 (9) , 1859-1862
- https://doi.org/10.1002/1097-0142(19850501)55:9<1859::aid-cncr2820550902>3.0.co;2-f
Abstract
Ependymoblastoma developed in a 28‐month‐old girl whose epileptic mother took diphenylhydantoin and methylphenobarbitone throughout pregnancy. The child was also shown to be a genetic carrier for ornithine transcarbamylase deficiency, an x‐linked inborn error of urea cycle metabolism. The possibility of transplacental carcinogenesis should be considered, as other juvenile embryonic tumors such as neuroblastoma, melanotic neuroectodermal tumor, and mesenchymoma have been reported in offspring after diphenylhydantoin use by the mother during pregnancy.This publication has 15 references indexed in Scilit:
- CHILDHOOD CANCER AND PREGNANCY DRUGSThe Lancet, 1981
- CHILDHOOD CANCER AND PREGNANCY DRUGSThe Lancet, 1981
- CANCER IN THE FETAL HYDANTOIN SYNDROMEThe Lancet, 1981
- Carrier detection in ornithine transcarbamylase deficiencyJournal of Inherited Metabolic Disease, 1980
- Survival after major burn complicated by gas gangrene, acute renal failure, and toxic myocarditis.BMJ, 1979
- Malignant Mesenchymoma and Birth DefectsJAMA, 1977
- FETAL HYDANTOIN SYNDROME AND NEUROBLASTOMAThe Lancet, 1976
- FETAL HYDANTOIN SYNDROME AND NEUROBLASTOMAThe Lancet, 1976
- U.S. childhood cancer deaths by cell type, 1960-68The Journal of Pediatrics, 1974
- The two “hit” and multiple “hit” theories of carcinogenesis.British Journal of Cancer, 1969